Efgartigimod is a medicine for generalized myasthenia gravis and CIDP, conditions where the immune system attacks the nerves or the links between nerves and muscles. It is given as an IV infusion (Vyvgart) or as an injection under the skin (Vyvgart Hytrulo). It works by lowering the levels of the harmful antibodies that cause muscle weakness.
Every report comes from a Lived member, sent anonymously.
Have you tried Vyvgart / Vyvgart Hytrulo (Efgartigimod Alfa) for Myasthenia Gravis?
Efgartigimod alfa is a prescription medicine for two autoimmune conditions in which the immune system makes antibodies that interfere with nerves or with the signal between nerve and muscle. It comes as two brands. Vyvgart is given as an intravenous (IV) infusion and is approved for adults with generalized myasthenia gravis (gMG), a condition that causes muscle weakness affecting more than the eyes, often including swallowing, speech, breathing or the limbs. Vyvgart Hytrulo is an injection under the skin, approved for adults with gMG and also for chronic inflammatory demyelinating polyneuropathy (CIDP), an inflammatory condition that damages the insulating coating of nerves and gradually weakens the arms and legs. For myasthenia gravis, both brands are approved for adults whether or not their blood tests show antibodies against the acetylcholine receptor (AChR, the muscle's docking site for the nerve's chemical signal). It is usually added to existing treatment rather than replacing it. For CIDP, it is an alternative for people who might otherwise rely on long-term intravenous immunoglobulin (IVIG, antibodies pooled from donated blood) or steroids, the standard first treatments.
Most antibodies in the blood are a type called IgG. Normally, a protein called the neonatal Fc receptor (FcRn) rescues IgG from being broken down, which keeps antibodies circulating far longer than they otherwise would. In myasthenia gravis, some of those long-lived antibodies are the harmful ones attacking the nerve-muscle connection. Efgartigimod is a fragment of an antibody designed to occupy FcRn. With the receptor blocked, IgG antibodies are cleared faster, so their levels fall, including the disease-causing ones. In clinical studies, the harmful antibody levels dropped by roughly 60% after a four-week course, and muscle strength and daily function tended to improve as they fell. The effect is temporary: antibody levels climb back after treatment stops, which is why it is given in repeated courses or ongoing doses. Vyvgart Hytrulo also contains hyaluronidase, an enzyme that briefly loosens the tissue under the skin so a large dose can be injected quickly; that tissue returns to normal within a day or two.
Vyvgart (IV) is given in a clinic or infusion center as a one-hour infusion once a week for four weeks. The dose is based on body weight. Vyvgart Hytrulo is a fixed-dose injection under the skin of the abdomen that takes under two minutes. It comes as a vial given by a healthcare professional or as a prefilled syringe that a patient or caregiver can use at home after training. For myasthenia gravis, both forms are given in treatment cycles: four weekly doses, then a break. When the next cycle starts depends on how symptoms respond, so the gap between cycles differs from person to person. For CIDP, Vyvgart Hytrulo is injected once a week on an ongoing basis rather than in cycles. A missed dose can usually be given up to three days late, after which the original schedule resumes. Before each new cycle, the care team checks whether any vaccines are due.
The most common side effects are respiratory infections such as colds, headache and urinary tract infections. With Vyvgart Hytrulo, reactions at the injection site (redness, itching, bruising, pain or a rash) are common, especially during the first cycle. They are usually mild, appear within a day and fade on their own. Some people also notice tingling or muscle aches. Allergic reactions can happen. Rash or hives, which can appear up to a few weeks after a dose, should be reported to the care team promptly. Rarely, a severe reaction (anaphylaxis) or a sudden drop in blood pressure causing fainting has occurred during or within an hour of a dose. Trouble breathing, swelling of the face, lips or throat, or fainting needs emergency help right away by calling 911. Some people have also had infusion or injection reactions with chills, shivering, a rise in blood pressure, or chest, belly or back pain. Anyone who has had a serious allergic reaction to efgartigimod or hyaluronidase should not receive it again.
Because efgartigimod lowers antibody levels, it can make infections more likely. A dose is usually postponed during an active infection, and fever or other signs of infection during treatment are worth reporting. Live vaccines are not recommended during treatment, so it helps to bring vaccinations up to date before starting. The same mechanism that clears harmful antibodies can also clear antibody-based medicines. It may lower the effect of immunoglobulin (IVIG or subcutaneous immunoglobulin, made from donated antibodies) and of monoclonal antibodies, a large group of lab-made antibody drugs used for many conditions. If someone needs one of these long term, the prescriber may weigh a different treatment. There are no human data on efgartigimod in pregnancy. It is expected to cross the placenta late in pregnancy and lower the antibodies a baby is born with, which can affect the timing of the baby's live vaccines. People who are pregnant, planning pregnancy or breastfeeding should discuss it with the prescriber; a pregnancy registry collects outcomes.
In the main myasthenia gravis trial, about two thirds of people with AChR antibodies had a meaningful, sustained improvement in daily activities such as talking, chewing, swallowing and getting up from a chair during the first cycle, compared with about 30% on placebo. For people without AChR antibodies, the benefit over placebo in a separate trial was present but smaller on average. As antibody levels recover after a cycle, symptoms can return, and that return guides when the next cycle starts. In CIDP, about two thirds of people improved enough during initial treatment to continue, and continuing the medicine delayed relapse compared with placebo. Not everyone responds, and some people's nerve symptoms worsened after switching from IVIG. Weakness that gradually gets worse after starting treatment or changing from another therapy should be reported to the prescriber, since it may mean the medicine is not working well enough. Efgartigimod is a long-term management tool rather than a cure, and regular neurology follow-up is used to judge whether it is helping.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Vyvgart / Vyvgart Hytrulo (Efgartigimod Alfa), what you've noticed, or ask the community a question.